Oncology Institute (TOIIW) Return on Capital Employed (2021 - 2026)

Oncology Institute (TOIIW) has 6 years of Return on Capital Employed data on file, last reported at 37.53% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 1031.0% year-over-year to 37.53%; the trailing twelve-month figure through Mar 2026 stood at 37.53% (up 1031.0% YoY), and the FY2025 full-year result was 36.92%, up 640.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 37.53%, up from 38.73% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 33.72% in Q4 2022 and bottomed at 49.24% in Q2 2022.
• The 5-year median for Return on Capital Employed is 44.18% (2023), against an average of 43.34%.
• The widest annual swing landed in 2022, when Return on Capital Employed sank 4452 bps; it then jumped 1031 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 33.72% in 2022, then declined by 28 bps to 43.02% in 2023, then retreated by 13 bps to 48.59% in 2024, then rose by 20 bps to 38.73% in 2025, then climbed by 3 bps to 37.53% in 2026.
• The last three Return on Capital Employed figures came in at 37.53% (Q1 2026), 38.73% (Q4 2025), and 42.76% (Q3 2025), per Business Quant data.

Peer Comparison